Table 3.

Three-way ANOVA was used to analyze effects of pre-session scopolamine on task performance.

Variable	Effect	F value	p value	Post hoc analysis
Rewards	Test type	13.57	4.22 × 10−3	Post-training (Sal) is significantly different from Perf (Pre-Scop) and Post-training (Scop) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	2.23	0.17
	Drug by Perf	107.2	1.16 × 10−6
	Drug by Post-training by Perf	3.84	0.079
Incorrect NPs	Test type	30.22	2.63 × 10−4	Post-training (Sal) is significantly different from Perf (Pre-Scop) and Post-training (Scop) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	0.94	0.35
	Drug by Perf	55.41	2.20 × 10−5
	Drug by Post-training by Perf	0.08	0.77
Inactive NPs	Test type	8.02	0.018	Post-training (Scop) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	9.07	0.013
	Drug by Perf	0.09	0.77
	Drug by Post-training by Perf	0.62	0.45
Tones	Test type	14.86	2.20 × 10−3	Post-training (Sal) is significantly different from Perf (Pre-Scop) and Post-training (Scop) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	2.55	0.14
	Drug by Perf	43.24	6.26 × 10−5
	Drug by Post-training by Perf	0.11	0.74
Hit rate	Test type	5.50	0.04	Post-training (Sal) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	0.53	0.48
	Drug by Perf	9.75	0.01
	Drug by Post-training by Perf	1.11	0.32
Receptacle entries	Test type	41.50	7.42 × 10−5	Post-training (Sal) is significantly different from Perf (Pre-Scop) and Post-training (Scop) is significantly different from Perf (Pre-Scop) (p < 0.05)
	Drug by Post-training	126.8	0.63
	Drug by Perf	25.46	5.02 × 10−5
	Drug by Post-training by Perf	0.08	0.77